MONTE ROSA THERAPEUTICS INC

Monte Rosa Therapeutics pioneers molecular glue therapies, targeting disease-causing proteins to improve survival and quality of life.

Monte Rosa Therapeutics is pioneering disease‑degrading “molecular glue” therapies, aiming to dismantle harmful proteins and boost patient outcomes while attracting investor confidence.

Monte Rosa Therapeutics Inc. has entered into a licensing agreement with Novartis, potentially worth up to $5.7 billion, to develop novel degraders for immune-mediated diseases.

Monte Rosa Therapeutics is pioneering a new approach to disease treatment with its molecular glue technology, aiming to degrade disease-causing proteins and transform patient outcomes.

Monte Rosa Therapeutics is pioneering a new approach to disease treatment with its molecular glues, which aim to dismantle disease-causing proteins and potentially transform patient care.